Individual Patient Compassionate Use of Fedratinib
ConditionMyelofibrosis
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorCelgene
About this trial
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib.
Expanded access is only available in markets where fedratinib is not yet approved.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Oral Fedratinib
Treatment groups
No treatment groups listed
Sponsors and collaborators
Celgene
Lead sponsor
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Collaborator
Source ClinicalTrials.gov